# Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Canonical URL: https://biopharmsignal.com/news/IMRX/immuneering-reports-17-3-months-median-overall-survival-in-first-line-metastatic-pancreatic-cancer-patients-treated-with-atebimetinib-plus-chemotherapy
Ticker: IMRX
Company: Immuneering
Source: Immuneering
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.immuneering.com
## Summary

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 - - Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related

## Article Body
- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 - - Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related
## Recent Company News
- 2026-06-25 13:46 EST — [Immuneering Appoints Andrew Gengos as Chief Financial Officer](https://biopharmsignal.com/news/IMRX/immuneering-appoints-andrew-gengos-as-chief-financial-officer) — Source: Immuneering
- 2026-06-25 13:46 EST — [Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer](https://biopharmsignal.com/news/IMRX/immuneering-announces-first-patient-dosed-in-pivotal-phase-3-mapkeeper-301-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer) — Source: Immuneering
- 2026-06-25 13:46 EST — [Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO](https://biopharmsignal.com/news/IMRX/immuneering-presents-compelling-17-3-month-median-overall-survival-and-favorable-tolerability-with-atebimetinib-chemotherapy-in-first-line-pancreatic-cancer-patients-at-asco) — Source: Immuneering
- 2026-06-25 13:46 EST — [Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy](https://biopharmsignal.com/news/IMRX/immuneering-reports-17-3-months-median-overall-survival-in-first-line-metastatic-pancreatic-cancer-patients-treated-with-atebimetinib-plus-chemotherapy) — Source: Immuneering
- 2026-06-25 13:46 EST — [Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/IMRX/immuneering-reports-first-quarter-2026-financial-results-and-provides-business-updates) — Source: Immuneering
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)